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EfavirenzThe xenotropic murine leukemia virus-related virus (XMRV) is a human retrovirus, recently isolated from
tissues of prostate cancer patients with impaired RNase L activity. In this study, we evaluated 10 licensed
anti-HIV-1 compounds for their activity against XMRV, including protease inhibitors (PI), nucleoside reverse
transcriptase (RT) inhibitors (NRTI), non-nucleoside RT inhibitors (NNRTI) and an integrase inhibitor. No PI
affected XMRV production; even high concentrations of Ritonavir failed to inhibit the maturation of XMRV
Gag polyproteins. Among the NRTI, NNRTI and integrase inhibitors used in this study, only AZT blocked
XMRV infection and replication through inhibition of viral reverse transcription. This sensitivity of XMRV to
AZT may be explained by the modest homology in the motif D sequences of HIV-1 and XMRV reverse
transcriptases. If XMRV becomes established as an etiological agent for prostate cancer or other diseases, AZT
may be useful for preventing or treating XMRV infections in humans.
© 2009 Elsevier Inc. All rights reserved.Prostate cancer is the most frequently diagnosed noncutaneous
malignancy among men in industrialized countries (Simard et al.,
2002). In the United States, one in eight men will develop prostate
cancer during his lifetime. Prostate cancer has a complex etiology
inﬂuenced by androgens, diet and other environmental and genetic
factors (Nelson et al., 2003). A positive family history is among the
strongest epidemiological risk factors for prostate cancer, and a
number of genetic mutations have been implicated in prostate cancer.
An R462Q mutation in the RNase L protein, an important effector of
the innate antiviral response, was implicated in up to 13% of
unselected prostate cancer cases (Casey et al., 2002). The link
between prostate cancer and the RNase L R462Q mutation, which
impairs its catalytic activity, suggested the possible involvement of a
viral infection in prostate cancer in individuals harboring the R462Q
variant. Indeed, Urisman et al. (2006) used a viral detection DNA
microarray composed of oligonucleotides corresponding to the
conserved sequences of all known viruses, and identiﬁed the
sequences of a novel human gammaretrovirus in cDNA samples
from 7 of 11 R462Q-homozygous cases, and in 1 of 8 heterozygous andedicine, Mayo Clinic College of
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y, Tokyo Medical and Dental
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ll rights reserved.homozygous wild-type cases. This newly identiﬁed virus was termed
as xenotropic murine leukemia virus (MLV)-related virus (XMRV).
Further study found XMRV infection in 8 of 20 R462Q homozygous
cases, while only 1 in 66 heterozygous and homozygous wild-type
homozygous cases (Urisman et al., 2006).
Gammaretroviruses such as MLV, feline leukemia virus and
Gibbon ape leukemia virus are associated with leukemogenesis in
their respective host species (Kawakami et al., 1972, 1967; Rask-
Nielsen, 1963). The two well-understood processes in gammare-
trovirus-mediated leukemogenesis are insertional activation of
proto-oncogenes and direct introduction of proto-oncogenes
through recombination with a retroviral genome (Fan, 1997).
XMRV is a gammaretrovirus, most closely related to xenotropic
MLV, and uses the same XPR1 (xenotropic and polytropic retrovirus
receptor 1) as their receptor (Battini et al., 1999; Dong et al., 2007).
Although the role of XMRV in prostate cancer remains to be
determined, XMRV infection has been observed in prostatic stromal
cells in vivo (Urisman et al., 2006) and in human 22Rv1 prostate
carcinoma cells (Knouf et al., 2009). The latter report suggests that
viral integration could contribute to oncogenesis through insertional
activation of an adjacent oncogene. Alternately, infection of prostatic
stromal cells could promote prostate cancer development by
secreting growth factors, cytokines or other factors that stimulate
cell proliferation or aid the tumor microenvironment.
Many anti-retroviral drugs are currently available for the highly
active anti-retroviral therapy (HAART) for HIV-1 treatment. In this
2 Rapid Communicationstudy, we screened the antiviral activities of 10 major antiviral drugs
on XMRV replication, and found that AZT strongly blocked XMRV
replication through inhibition of viral reverse transcription. If XMRV is
established as a human pathogen AZT could be useful or treating or
preventing these infections.Production of a GFP-carrying XMRV
In order to monitor XMRV production and infectivity, we
generated a GFP-expressing XMRV (XMRV-GFP) by cross-packaging
a GFP-encoding MLV vector genome with a full-length XMRV clone
VP62. Semi-conﬂuent 293T cells in a 6-well plate were co-transfected
with a GFP-carrying MLV-based gene transfer vector construct (Noser
et al., 2006) and an infectious XMRV proviral plasmid, VP62/
pcDNA3.1(-) (Dong et al., 2007) using 6 μl of FuGene6 (Roche Applied
Science, Indianapolis, IN). Seventy-two hours post-transfection, cell
culture supernatants were harvested and ﬁltered through 0.45 μm-
ﬁlters. For titration, human LNCaP, 293T and murine NIH3T3 cells
were infected with increasing amounts of GFP-carrying XMRV. Two
days after infection, viral titers were determined by enumerating the
GFP-positive cell populations by ﬂow cytometry. XMRV-GFP titers
reached 2.4×106 and 2.5×105 infectious units/ml (IU/ml) in LNCaP
and 293T cells, respectively (Fig. 1A). As expected, murine NIH3T3
cells were not permissive to XMRV-GFP (Fig. 1A).Fig. 1.No evidence of anti-XMRV activity in HIV protease inhibitors. (A) LNCaP, 293T and NIH
cell populations were analyzed by ﬂow cytometry. (B) GFP-carrying XMRV was produced in
DMSO (Control). Inﬂuence of drug treatment on viral infectivity was determined by infe
compounds. (C) 293T and LNCaP cells were treated with 30 nM of a PI for 72 h, and cell viabi
triplicated experiments with standard deviation. (D) GFP-carrying XMRV was produced in 2
were determined by FACS. Equivalent amounts of DMSOwere used as controls. (E) 293T and
MTT assay. (F) 293T cells were transfected with a XMRV proviral DNA plasmid, treated with
lysates were analyzed to detect XMRV precursor Gag (Pr-Gag) and proteolytically cleaved
antibody. (G) 293T cells were transfected with a HIV-1 provirus plasmid, pNL4-3. HIV-1-prod
precursor Gag (Pr-gag) and mature capsid (CA) proteins.No evidence of anti-XMRV activity in HIV protease inhibitors (PIs)
First, we examined the inﬂuence of PI treatment on the late phase
of XMRV replication. The GFP-carrying XMRV was produced in the
presence of commonly used PIs including Ritonavir (Kempf et al.,
1995; Molla et al., 1996), Saquinavir (Martin et al., 1991) or Indinavir
(Vacca et al., 1994). As a control, an equivalent amount of DMSO was
added in the culture supernatant. In order to rule out the possibility
that impaired cell viability resulted in the reduced XMRV production
or infectivity, we evaluated the toxicity of PIs in 293T and LNCaP cells
by MTT assay (Millipore, Billerica, MA). Indinavir and Saquinavir
treatment of XMRV producing cells did not strongly affect the
resulting XMRV infectivity (Fig. 1B), suggesting the lack of antiviral
activity against XMRV. In contrast, Ritonavir reduced the XMRV-GFP
titer approximately 3-fold (Fig. 1B). Since treatment of 293T cells with
Ritonavir at the ﬁnal concentration of 30 nM did not show strong
toxicity (Fig. 1C), we focused on Ritonavir for its possible anti-XMRV
activity. Treatment of XMRV-producing cells with increasing amounts
of Ritonavir revealed that 150 nM, but not 6 and 30 nM, of Ritonavir
strongly blocked the XMRV production (Fig. 1D). The effects on XMRV
were well-correlated with its dose-dependent toxicity in 293T cells
(Fig. 1E). In order to address whether the reduced XMRV production
was due to the inhibition of viral protease activity or the toxicity of
Ritonavir on 293T cells, we tested the inﬂuence of Ritonavir treatment
on thematuration of XMRVGag polyproteins. As a positive control, we3T3 cells were infected with GFP-carrying XMRV. Two days after infection, GFP-positive
the presence of 30 nM of Ritonavir, Indinavir and Saquinavir, or equivalent amount of
cting 293T cells with the GFP-carrying XMRV produced in the presence of antiviral
lity was determined by MTT assay and shown as the average of absorbance (630 nm) of
93T cells in the presence of increasing amounts of Ritonavir and the resulting viral titers
LNCaP cells were treated with 6, 30 and 150 nM of Ritonavir for 3 days, and subjected to
various concentrations (6, 30, 150 nM) of Ritonavir or equivalent amount of DMSO. Cell
mature capsid protein (CA). As a loading control, β-actin was detected by anti-β-actin
ucer cells were treated with 6 nM of Ritonavir, and cell lysates were analyzed for HIV-1
3Rapid Communicationused an infectious molecular clone of HIV-1, pNL4-3. Although 6 nM of
Ritonavir potently blocked the cleavage of HIV-1 Gag polyproteins
into mature Capsid protein, 6 or 30 nM of Ritonavir did not affect
XMRV Gag maturation patterns. Treatment with 150 nM of Ritonavir
strongly reduced the levels of XMRV Gag in the producer cells. This is
most likely due to the toxicity from the high concentration of
Ritonavir in 293T cells (Fig. 1E), because the treatment did not change
XMRV Gag maturation patterns and mature XMRV capsid was
detected in the producer cell lysate. We concluded that XMRV is
resistant to the licensed HIV-1 protease inhibitors, Ritonavir,
Saquinavir and Indinavir.
Azidothymidine (AZT) inhibits XMRV infection through inhibition
of viral reverse transcription
Next, we examined the anti-XMRV activity of licensed antiretro-
viral drugs including nucleoside reverse transcriptase inhibitors
(NRTIs; AZT, 3TC, Tenofovir and D4T; Coates et al., 1992; Ruprecht
et al., 1986; Tsai et al., 1995), non-nucleoside reverse transcriptase
inhibitors (NNRTI; Efavirenz and Nevirapine; Merluzzi et al., 1990;
Young et al., 1995) and an integrase inhibitor (118-D-24). LNCaP cells
were infected with XMRV-GFP in the presence of 30 nM of anti-
retroviral drugs. Among NRTIs tested, AZT inhibited XMRV infection
up to 25-fold, while 3TC, Tenofovir and Efavirenz showed minimal or
no inhibitory effects on XMRV infection (Fig. 2A). Similarly, NNRTI andFig. 2. Inﬂuence of RT inhibitors on XMRV infection. (A) LNCaP cells were infected with
Nevirapine and 118-D-24. As a control, equivalent amount of DMSO was used. Three days af
maintained in the presence of 30 nM of the indicated antiretroviral compounds for 72 h, and
carrying XMRV in the presence of 6, 30 and 150 nM of AZT or equivalent amount of DMSO. T
treated with 6, 30 and 150 nM of AZT for 3 days, and subjected to MTT assay. (E) LNCaP c
equivalent amounts of DMSO. Total cellular DNA was isolated at 8 and 24 h post infection.
system.integrase inhibitors did not strongly affect XMRV infection (Fig. 2A).
Marginal toxicity was observed in the LNCaP cells treated with 30 nM
of the anti-retroviral drugs (Fig. 2B). To further understand the AZT-
mediated block of XMRV infection, we examined the relationship
between inhibition of viral infectivity and drug-induced toxicity using
cells treated with 0, 6, 30 or 150 nM of AZT. As shown in Fig. 2C, 6 nM
of AZT inhibited XMRV infection by 20-fold. In contrast, 150 nM of AZT
was required to get 50% reduction in cell viability (Fig. 2D),
demonstrating AZT as a potent anti-XMRV drug. To further examine
the inﬂuence of AZT treatment on XMRV reverse transcription, we
designed quantitative PCR probe/primers based on XMRV gag, pol
and env genes and examined the levels of reverse transcripts in the
XMRV-infected cells. LNCaP cells were infected with benzonase-
treated XMRV in the presence of 30 nM of AZT, and total cellular DNA
was isolated by QIAGEN DNA blood kit at 8 and 24 h post infection.
The copy numbers of viral reverse-transcripts were determined by ABI
Real Time PCR system using following primers/probes: gag (forward
primer, 5′-CAGTTGCTCTTAGCGGGTCT-3′; reverse primer, 5′-TTAC-
CTTGGCCAAATTGGTG-3′; probe “Roche library #51”, 5′-FAM-ggcag-
gag-3′), pol (forward primer, 5′-TAAAGGCGGCGACAACTC-3′; reverse
primer 5′-GGTTTTGAGAACGCTGGACT-3′; probe “Roche library #150”,
5′-FAM-gaacagca-3′); env (forward primer, 5′-CCTAGTGGCCACCAAA-
CAAT-3′; reverse primer, 5′-GGCCCCAAGGTCTGTATGTA-3′; probe
“Roche library #1”, 5′-FAM-gctccagg-3′). As shown in Fig. 2E, AZT
treatment reduced the copy numbers of XMRV cDNA in the infectedGFP-carrying XMRV in the presence of 30 nM of AZT, 3TC, Tenofovir, D4T, Efavirenz,
ter infection, GFP-positive cell populations were analyzed by FACS. (B) 293T cells were
cell viability was assessed byMTT assay. (C) LNCaP cells were infected with 20 μl of GFP-
hree days after infection, viral infectivity was determined by FACS. (D) LNCaP cells were
ells were infected with benzonase-treated XMRV in the presence of 30 nM of AZT or
The copy numbers of viral reverse-transcripts were determined by ABI Real Time PCR
4 Rapid Communicationcells up to 20-fold, which correlated well with the reduced XMRV
infectivity upon AZT treatment. We therefore concluded that AZT
blocks XMRV infection through inhibition of viral reverse
transcription.
Inﬂuence of AZT treatment on XMRV replication
AZT strongly blocked single-round XMRV infection without
showing marked toxicity (Fig. 2). We therefore assessed whether
AZT could inhibit XMRV replication. XMRV-infected LNCaP cells were
mixed with uninfected LNCaP cells at day 0, and cultured for 3 weeks
in the presence of 30 nM AZT. As a control, co-cultured cells were
maintained in the presence of equivalent amount of DMSO. Viral
replication was monitored by the secreted virion-associated RT
activity (Reverse Transcriptase Assay Colorimetric (Roche), with
additional 10 mM MnCl2 in the reaction buffer). Although robust
XMRV replication in DMSO-treated cells was evident by the RT
activity in the culture supernatants, AZT treatment could maintain the
RT production at low levels (0.2 to 0.3 ng RT/ml) for 3 weeks. WhenFig. 3. (A) Inﬂuence of AZT treatment on XMRV replication. LNCaP cells were infected with
XMRV-infected LNCaP cells were maintained in the presence of 30 nM AZT or DMSO. Culture
13, AZT treated cells were divided into two culture bottles; one wasmaintained in 30 nMAZT
treated with DMSO or 30 nM AZT for additional 8 days. (B) Alignment of portions of HIV-1
dependent DNA polymerases including HIV-1, XMRV, MLV, PERV and hTERT. The HIV-1 mot
AZT (T215Y, K220Q) are indicated by arrows. (C) Alignment of portions of HIV-1 and XMRV
polymerase active-site YMDD and the LPQG motif are underlined. Codons associated with re
Efavirenz (K103N), Nevirapine (V106A), 3TC (K65R/M184V) and AZT (T215Y, K220Q) areAZT was removed from the culture media at 2 weeks after treatment,
rapid increases in the RT activity were observed (Fig. 3A). In contrast,
when AZT was added to the DMSO-treated cells at 2 weeks after co-
cultivation, no reduction in RT activity was observed in the XMRV-
infected culture (Fig. 3A). These observations suggest that AZT does
not eliminate the virus or virus-infected cells but blocks new XMRV
infection in uninfected cells.
In this study, we evaluated 10 licensed anti-HIV-1 retroviral drugs
for their activity against XMRV. We found that no protease inhibitors
strongly blocks XMRV production. Among RT and integrase inhibitors
tested, only AZT could efﬁciently block XMRV infection and
replication through inhibition of viral reverse transcription. Our
ﬁndings are thus consistent with a recent study demonstrating
inhibition of XMRV replication by AZT in human prostate cancer cell
line DU145 (Hong et al., 2009).
Despite the structural diversity of the compounds and the use of
concentrations that were more than 10-fold higher than those to
block HIV-1, XMRV showed no marked susceptibility to HIV-1
protease and integrase inhibitors. This is likely due to the structuralXMRV stock for a week, and then co-cultured with uninfected LNCaP cells (day 0). The
supernatants were collected every 2 days. Cells were passaged on days 7 and 13. On day
and the other in DMSO. Similarly, DMSO-treated cells were divided into two bottles and
and XMRV RT amino acid sequences. Amino acid sequence alignments of various RNA-
if D amino acid residues were underlined. Codons associated with resistance of HIV-1 to
RT amino acid sequences. Identical residues are indicated with an asterisk. The HIV-1
sistance of HIV-1 to multi-nucleoside analogs (Q151M), Tenofovir (K65R), D4T (V75I),
indicated by arrows.
5Rapid Communicationdifferences between XMRV and HIV-1 viral enzymes. In this context, it
is notable that AZT could inhibit the reverse transcriptase activity of
two highly divergent retroviruses. The determinant of the sensitivity
of HIV-1 RT to AZT has been extensively studied (Larder et al., 1989).
Although many mutations in the HIV-1 RT were reported to be
responsible for AZT resistance, the motif D in the palm domain of RT
appears to play a critical role for the resistance against AZT (Canard et
al., 1999; Lacey and Larder, 1994). Mutations in the amino acid
residues Thr-215 and Lys-220 can render HIV-1 RT resistant to AZT
through enhanced excision of the chain-terminating AZT-5′-mono-
phosphate (Boyer et al., 2001a, 2002; Saraﬁanos et al., 2002) or
through changing the interaction with the incoming nucleotide
(Canard et al., 1999; Gao et al., 1992; Lopez-Galindez et al., 1991;
Matamoros et al., 2004). Intriguingly, other RNA-dependent DNA
polymerases, including retroviral and mammalian enzymes, have a
motif D in their palm regions (Armanios et al., 2005; Canard et al.,
1999). The amino acid sequence of XMRV motif D shows a modest
homology to its HIV-1 counterpart and the amino acid residue
corresponding to the critical Lys-220 of HIV-1 RT is conserved (Fig.
3B). The XMRV motif D shows 100% homology to those of other
gammaretroviruses, such as MLV and porcine endogenous retrovirus
(PERV) (Fig. 3B). As expected, human telomerase reverse transcrip-
tase (hTERT) shows limited homology to the retroviral motif D
sequences, yet the amino acid residue corresponding to the HIV-1 RT
Lys-220 is conserved (Fig. 3B). It is intriguing to note that AZT can also
inhibit the reverse transcriptase activities of MLV, PERV and hTERT
(Mo et al., 2003; Qari et al., 2001; Ruprecht et al., 1986; Sharpe et al.,
1988; Strahl and Blackburn, 1996), although the precise mechanisms
of inhibition remain to be determined. We speculate that the motif D
sequences, particularly the conserved Lys residues, of retroviral RTs or
hTERT determine their sensitivity to AZT. Verifying the possible role of
XMRV motif D in the sensitivity to AZT will require further drug
susceptibility analysis of site-speciﬁc XMRVmutants. Althoughwe did
not observe the emergence of an AZT-resistant XMRV mutant during
the ﬁrst 3 weeks of treatment, it will be of interest to assess whether
XMRV can escape from AZT by naturally acquiring mutation(s) in the
RT upon long-term culture in the presence of AZT.
In contrast to AZT, other HIV-1 RT inhibitors did not show notable
anti-XMRV activity. To better understand the basis of XMRV
susceptibility to the RT inhibitors tested in this study, we compared
the amino acid sequences of the XMRV and HIV-1 RTs. Although the
mechanisms of HIV-1 resistance to RT inhibitors cannot be explained
by single amino acid mutations, we indicated common RT inhibitor
resistance-related amino acid residues of HIV-1 RT by arrows (Fig.
3C). Although Q151M mutation in the LPQG motif of HIV-1 RT is
associated with resistance to multiple nucleoside analogs (Shirasaka
et al., 1995), this motif is fully conserved in XMRV RT (Fig. 3C), thus
ruling out the possible role of this domain in the XMRV resistance
against many RT inhibitors. Mutations K65R, V75I, K103N, V106A and
K65R/M184V in HIV-1 RT are associated with resistance to Tenofovir,
D4T, Efavirenz, Nevirapine and 3TC, respectively (Gu et al., 1994;
Masquelier et al., 2004; Nitanda et al., 2005; Quan et al., 1999; Ren et
al., 2000; White et al., 2004). XMRV RT has a Lys at the residue
corresponding to Lys-65 in HIV-1 RT, which does not support a role of
this residue in the observed resistance to Tenofovir. It is plausible that
the amino acid residues proximal to Lys-65 render the XMRV RT
resistant to Tenofovir. In contrast, XMRV has Gln, Ser, Leu and Val at
the residues corresponding to 75-Val, 103-Lys, 106-Val and 184-Met,
respectively, which may explain the observed XMRV resistance to
D4T, Efavirenz, Nevirapine and 3TC.
Although we did not see notable antiviral effects by Indinavir on
XMRV production, Powell et al. (1999) reported the inhibition of MLV
production by Indinavir. It is possible that the toxicity of Indinavir
resulted in the block of MLV production in this particular study
(Powell et al., 1999). Alternatively, the variations in the pol gene
between MLV and XMRV changed the susceptibility of these tworelated retroviruses to Indinavir. In addition, it will be of interest to
assess whether didanosine (ddI) can block XMRV infection, as ddI has
minimal antiviral effects against MLV (Powell et al., 1999; Boyer et al.,
2001b).
Many retroviruses are known to cause cancer. Well-characterized
mechanisms for tumorigenesis include the insertional activation of
host oncogenes or introduction of acquired host-derived oncogenes in
the infected cells (Lund et al., 2002; Peters et al., 1983; Sheiness et al.,
1980; Steffen, 1984). Some retroviruses, such as humanT cell leukemia
virus and Jaagsiekte sheep retrovirus, are known to encode viral
proteins which induce abnormal cell growth by activation of growth-
promoting genes or by inhibiting tumor suppressor genes (Seiki et al.,
1984; Tanaka et al., 1990; Wootton et al., 2005). The role of XMRV in
prostate cancer development remains to be determined. However, the
initial study identiﬁed XMRV-infected cells as stromal cells, rather
than carcinoma cells (Urisman et al., 2006), suggesting that XMRVmay
support prostate cancer development through indirectly promoting
abnormal cell growth. If XMRV is established as a contributing agent in
prostate cancer, AZT may be able to prevent/slow prostate cancer
development inXMRV-infectedpopulations. It is however notable that
a recent study have identiﬁed a commonly used prostate carcinoma
cell line, 22Rv1, to consist primarily of a single clone of cells with
multiple integrated copies of XMRV (Knouf et al., 2009), which may
suggest an alternative, insertional mutagenesis-mediated prostate
cancer development in XMRV-infected subjects. Our result indicates
that AZT blocks XMRV infection, but does not eliminate the infected
cells (Fig. 3A). If insertional mutagenesis is the primary mode of
XMRV-mediated tumorigenesis, AZT treatment is unlikely to block the
progression of XMRV-positive prostate cancers. In this case, AZT may
be used to prevent/control XMRV infection, particularly in high-risk
subjects with a homologous RNase L R462Q mutation. Further
understanding of the role of XMRV in prostate cancer development
is necessary for the possible use of AZT to control prostate cancers in
XMRV-infected patients.
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